Aandeel LXRX LEXICON PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Lexicon Pharmaceuticals, Inc.

Aandelen

LXRX

US5288723027

Geschatte realtime Cboe BZX
Andere beurzen
 18:37:05 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
1,575 USD +2,27% Intraday-grafiek van Lexicon Pharmaceuticals, Inc. -4,55% +2,94%
22/04 Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day
25/03 Lexicon Pharmaceuticals dient prospectus in voor secundaire aanbieding MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Lexicon Pharmaceuticals to Host 2024 Investor Day
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care Stocks Decline in Afternoon Trading
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin
Lexicon: Q4 Earnings Snapshot
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers LXRX
  4. Nieuws Lexicon Pharmaceuticals, Inc.
  5. Andere talen